Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C)

Authors :: Stephen P. Hack
Victoria Atkinson
James Larkin
Luis de la Cruz-Merino
Michele Maio
Daniil Stroyakovskiy
Grant A. McArthur
Caroline Dutriaux
Claus Garbe
Ilsung Chang
Karen Bartley
Lev V. Demidov
Brigitte Dréno
Antoni Ribas
Mario Mandalà
Gabriella Liszkay
Luc Thomas
Paolo A. Ascierto
Source :: Journal of Clinical Oncology. 33:9021-9021
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: 9021 Background: The phase 3 coBRIM study showed significant improvement in progression-free survival in pts with metastatic melanoma on V + C compared with those on V and placebo (P) (HR, 0.51; 95...

Subjects :: Cobimetinib
Oncology
Cancer Research
medicine.medical_specialty
Metastatic melanoma
business.industry
Placebo
Surgery
chemistry.chemical_compound
Quality of life
chemistry
Internal medicine
medicine
In patient
Vemurafenib
business
medicine.drug

Full Text Access

Tools